Artificial intelligence (AI) tools developed by Etiometry may help to predict, among other outcomes, the length of a patient’s…
Articles by Marisa Wexler, MS
A weight-based dose regimen of Uptravi (selexipag) for children with pulmonary arterial hypertension (PAH) achieves drug exposure similar…
Two Phase 3 clinical trials are now recruiting participants to test Tenax Therapeutics‘ experimental therapy TNX-103 (oral levosimendan) in…
A committee of the European Medicines Agency (EMA) has recommended expanding the indication for Winrevair (sotatercept-csrk), Merck’s approved…
Altered activity of a protein called PUM1 plays a key role in the development of pulmonary hypertension (PH), according…
Merck Canada has taken what it called a “critical step” toward making its approved therapy Winrevair (sotatercept-csrk) — which…
Merck is planning a Phase 3 trial testing Winrevair (sotatercept-csrk) in people with combined post- and precapillary pulmonary hypertension…
CM5480, an experimental therapy being developed by Calcimedica, improved blood flow and heart-function measures in a rat model…
The investigational treatment TX45 may help improve heart function and circulatory health in people with pulmonary hypertension and heart…
The advocacy organization Phaware has launched a new mobile app to help people living with pulmonary hypertension (PH)…
The U.S. Food and Drug Administration (FDA) has approved updated prescribing information for Merck‘s…
A new experimental therapy for pulmonary arterial hypertension (PAH), called ALG-801, has shown superior efficacy over current standard-of-care treatments…